Solu Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, pioneering a novel class of antibody therapeutics that unlock cell-surface targets by combining small molecules with effector antibodies through proprietary linker technology. -
View it on GitHub